The Mitris valve is a bovine pericardial bioprosthetic heart valve designed specifically for the mitral position, manufactured by Edwards Lifesciences using their RESILIA tissue technology. It entered clinical use as an evolution of older biological valve designs, with changes aimed at reducing calcification, improving how the valve fits inside the heart, and potentially lasting longer than earlier-generation tissue valves. Early and mid-term clinical results have been encouraging, though the valve is still relatively new and long-term data are still accumulating.
What the Mitris Valve Actually Is
When the mitral valve between the left atrium and left ventricle becomes too diseased to repair, surgeons replace it with either a mechanical valve (made of metal and carbon) or a bioprosthetic valve (made from animal tissue). Each type carries trade-offs. Mechanical valves are extremely durable but require lifelong blood-thinning medication. Bioprosthetic valves let most patients avoid long-term anticoagulation, but they wear out over time, sometimes requiring a second operation a decade or more down the road.
The Mitris RESILIA valve is the latest attempt to close that durability gap. It uses cow pericardium (the tough sac surrounding the heart) that has been treated with a proprietary process designed to resist the calcium buildup that gradually stiffens and destroys tissue valves. The valve also has several structural engineering changes compared to its predecessors, aimed at making it easier to implant and less likely to interfere with nearby heart structures.
Design Features That Set It Apart
Bioprosthetic mitral valves have historically been adapted from aortic valve designs, and the fit has never been perfect. The mitral annulus (the ring of tissue where the valve sits) is saddle-shaped rather than circular, which means a flat, rigid sewing cuff can create problems during implantation. The Mitris valve addresses this with a refined saddle-shaped sewing cuff that is materially softer than the one used on its predecessor, the Perimount Magna Mitral Ease valve. That softer cuff conforms more naturally to the three-dimensional shape of the mitral annulus.1PubMed Central. Early Haemodynamic Performance and Clinical Outcomes of a Novel Bioprosthetic Mitral Valve
The valve also sits lower inside the heart than older models. This low-profile design, combined with a foldable stent frame, reduces the chance that the valve’s supporting structures will jut into the left ventricular outflow tract, the narrow passageway blood uses to exit the heart through the aortic valve. Outflow-tract obstruction is a recognized complication of mitral valve replacement, and it can happen even when surgeons remove the front leaflet of the native valve before sewing in the prosthesis.2PubMed Central. Left ventricular outflow tract obstruction after bioprosthetic mitral valve replacement with posterior mitral leaflet preservation A valve that takes up less space inside the ventricle reduces that risk, which is especially helpful in patients with a thickened heart wall or a naturally small outflow tract.3The Annals of Thoracic Surgery. Successful Double Valve Replacement Using the Novel Mitris Resilia Mitral Valve
That low profile and flexible frame also matter when both the mitral and aortic valves need replacement at the same time. A bulky mitral prosthesis can crowd the aortic valve or make it hard to seat the aortic prosthesis properly. The Mitris valve’s compactness was highlighted in case reports of successful double valve replacement, where the valve’s design helped avoid mechanical interference between the two prostheses.4The Annals of Thoracic Surgery. Successful Double Valve Replacement Using the Novel Mitris Resilia Mitral Valve
RESILIA Tissue and the Calcification Problem
The single biggest reason tissue valves fail is calcification. Over years, calcium deposits accumulate in the valve leaflets, making them stiff and leaky. A major contributor to this process is residual glutaraldehyde, the chemical used to preserve the animal tissue. Glutaraldehyde cross-links the collagen in the pericardium so the body does not immediately reject it, but leftover aldehyde molecules act as seeds for calcium crystal formation.
RESILIA tissue goes through an additional treatment step that dramatically reduces residual aldehyde content. In laboratory testing, standard glutaraldehyde-fixed tissue contained roughly 226 nanomoles of bound aldehyde per gram. An earlier anti-calcification treatment (ThermaFix) cut that to about 102. RESILIA tissue brought it down further to about 33, a roughly seven-fold reduction compared to standard fixation.5Journal of Materials Science: Materials in Medicine. The association of bound aldehyde content with bioprosthetic tissue calcification When these tissues were implanted in animal models to test calcium uptake, the results tracked closely with aldehyde content. RESILIA tissue accumulated a median of about 10 micrograms of calcium per milligram of tissue, compared to roughly 227 for standard glutaraldehyde-fixed tissue.6Journal of Materials Science: Materials in Medicine. The association of bound aldehyde content with bioprosthetic tissue calcification
This is bench and animal data, not a guarantee of how the tissue behaves inside a human heart over 15 or 20 years. But the magnitude of the difference is striking enough that it forms the central argument for why RESILIA-based valves, including the Mitris, might outlast their predecessors.
What the Clinical Trial Data Show
The primary clinical evidence for the Mitris valve comes from the COMMENCE trial, a prospective study that tracked patients who received RESILIA-tissue mitral valves. At the five-year mark, the probability of being free from structural valve deterioration was about 99 percent, and freedom from reoperation was about 97 percent. Five-year freedom from all-cause mortality was about 80 percent, a figure that reflects the overall health of the patient population (many of whom had serious heart disease) rather than a failing of the valve itself. Hemodynamic measurements stayed stable throughout follow-up, and the few valvular leaks detected were mild and not clinically concerning.7PubMed Central. Mid-term outcomes of the COMMENCE trial investigating mitral valve replacement using a bioprosthesis with a novel tissue
A separate analysis looking at both first-time and redo mitral valve replacements with the Mitris RESILIA prosthesis reported three-year outcomes. Freedom from all-cause mortality was 89 percent, freedom from reoperation was 99 percent, and freedom from structural valve deterioration was 100 percent at three years, with no significant differences between patients getting the valve for the first time and those replacing a previously implanted valve. Pressure gradients and valve opening areas remained stable over time, and no major leaking around the valve was detected.8Annals of Thoracic Surgery Short Reports. Clinical Outcomes of First-Time and Redo Mitral Valve Replacement Using MITRIS RESILIA Bioprosthesis
Those numbers are reassuring, but five years is still early for a device expected to last well beyond a decade. The real test for any tissue valve is what happens between years 8 and 15, when calcification and leaflet degeneration traditionally accelerate. The RESILIA tissue platform does show encouraging comparative data in the aortic position, where propensity-matched analysis found that RESILIA-based valves had roughly 1 percent structural deterioration at mid-term follow-up compared to about 5 percent for a conventional bioprosthesis.9PubMed Central. Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses That aortic data cannot be directly transplanted to the mitral position, where the valve faces different mechanical stresses, but it adds to the case that the tissue technology genuinely slows deterioration.
The Question of Age and Who Should Get a Tissue Valve
For decades, guidelines recommended mechanical valves for younger patients (loosely defined as under 50 to 65, depending on the guideline and the valve position) because tissue valves were expected to wear out while the patient was still relatively young, requiring risky reoperation. That calculus has been shifting. As bioprosthetic durability improves, the trade-off changes: avoiding years of warfarin (with its bleeding risks, dietary restrictions, and regular blood monitoring) starts looking more appealing even for patients who might outlive their first tissue valve.
Research into bovine pericardial mitral valve replacements has argued that these valves are a durable option even in younger patients and that the opportunity to avoid anticoagulation and the associated risks of a mechanical valve may justify revising the current age thresholds downward.10PubMed. Should mitral valve replacement age guidelines be lowered due to better bioprosthetic mitral valve durability? This argument is strengthened by the growing availability of valve-in-valve procedures, where a catheter-delivered valve can be placed inside a failing surgical bioprosthesis without repeat open-heart surgery. If a tissue valve does eventually wear out, a second intervention may be far less invasive than it used to be.
Still, the picture is not entirely settled. Current guidelines from major cardiac surgery societies have not yet formally lowered the age cutoffs, partly because long-term data on the newest tissue valves (including the Mitris) are still maturing. For a 45-year-old facing mitral valve replacement, the decision between mechanical and bioprosthetic remains highly individual, involving bleeding risk, lifestyle, tolerance for blood-monitoring obligations, and how comfortable the patient is with the possibility of a future re-intervention.
Blood Thinners After Mitral Valve Replacement
One of the main appeals of any bioprosthetic valve is the option to stop anticoagulation after the initial healing period. Typically, patients who receive a tissue valve in the mitral position are placed on warfarin for the first three to six months after surgery, after which many can transition to aspirin alone. This stands in contrast to mechanical mitral valves, which require lifelong warfarin with a target blood-thinning range that demands frequent lab checks.
There are exceptions, though, and the Mitris valve is not immune to clot-related problems. A published case described a patient who received a 27 mm Mitris RESILIA valve and developed thrombotic valve dysfunction despite being on warfarin. In that patient, the underlying problem was a rare blood disorder (hypereosinophilic syndrome) combined with an unusual type of mitral annular calcification, both of which created an abnormally clot-prone environment that overwhelmed standard anticoagulation. The case ultimately required valve re-replacement.11European Heart Journal – Case Reports. Thrombotic prosthetic valve dysfunction requiring valve re-replacement after mitral valve replacement for caseous calcification with hypereosinophilic syndrome
That case is unusual and should not alarm the typical patient receiving a Mitris valve. But it underscores that the valve itself does not eliminate clot risk entirely. Patients with atrial fibrillation, clotting disorders, or other prothrombotic conditions may still need long-term anticoagulation regardless of which bioprosthetic valve they receive. The decision about when and whether to stop blood thinners is always individualized.
Outflow-Tract Obstruction and Why Valve Profile Matters
Left ventricular outflow tract obstruction, or LVOTO, is a serious but uncommon complication of mitral valve replacement. It happens when the prosthetic valve or its supporting structures physically block the path blood takes as it exits the left ventricle toward the aortic valve. Patients with a small ventricular cavity, a thickened septum, or a narrow outflow tract are at higher risk. Older, taller-profile bioprostheses are particularly prone to this problem; case reports have documented peak pressure gradients across the obstruction as high as 64 mmHg, enough to significantly impair cardiac output.12PubMed Central. Left ventricular outflow tract obstruction after bioprosthetic mitral valve replacement with posterior mitral leaflet preservation
The Mitris valve’s low-profile design and foldable stent system were engineered with exactly this problem in mind. By keeping the valve’s hardware closer to the annular plane and out of the ventricle’s interior, the risk of mechanical conflict with the outflow tract is reduced. For patients who are anatomically predisposed to this complication, the Mitris may offer a safety advantage over bulkier alternatives, though direct head-to-head comparison data are limited.
Redo Operations and the Mitris Valve
A meaningful number of patients requiring mitral valve replacement have already had a previous valve operation. These redo procedures are technically more challenging: scar tissue from the first surgery complicates access, and the anatomy may be distorted. How a new valve performs in this setting matters.
The available evidence suggests the Mitris valve performs similarly in first-time and redo patients. The study examining both populations found no significant differences in three-year freedom from mortality, reoperation, stroke, or structural deterioration between the groups.13Annals of Thoracic Surgery Short Reports. Clinical Outcomes of First-Time and Redo Mitral Valve Replacement Using MITRIS RESILIA Bioprosthesis The valve’s softer, more conformable sewing cuff may help in redo cases, where scarring and distortion of the mitral annulus can make seating a rigid prosthesis more difficult. That said, sample sizes in the redo group are modest, and more data will be needed before strong conclusions can be drawn.
How It Compares to Repair
It is worth noting that for many types of mitral valve disease, particularly degenerative disease where the leaflets prolapse, repair rather than replacement remains the preferred operation. A skilled surgeon reshaping the native valve avoids the limitations of any prosthesis. Guidelines consistently recommend repair over replacement when it is feasible, and that recommendation has not changed with the arrival of the Mitris valve.
Where the Mitris and other bioprosthetic valves become important is in cases where repair is not possible: rheumatic disease that has severely scarred and thickened the leaflets, heavily calcified annuli, failed prior repairs, or mixed valve pathology that cannot be adequately corrected by repair techniques. In those scenarios, the choice shifts to which replacement option best serves the patient, and the Mitris represents the current leading-edge option among tissue valves for the mitral position.
What We Are Still Waiting to Learn
The elephant in the room with any new tissue valve is durability beyond the medium term. Five years of data look good, and the underlying tissue science gives reason for optimism, but tissue valves have historically shown their weaknesses between 8 and 15 years. The COMMENCE trial and related registries are still following patients, and every additional year of data will sharpen the picture of how long the Mitris valve truly lasts in a working human heart.
There is also the open question of valve-in-valve compatibility. As catheter-based techniques mature, the ability to implant a new valve inside a failing surgical bioprosthesis without reopening the chest has become an important consideration in prosthesis selection. The internal dimensions, stent geometry, and radiopacity of the surgical valve all affect how well a future transcatheter valve will seat. Edwards Lifesciences has designed its newer surgical valves with this possibility in mind, but long-term valve-in-valve outcomes specifically for the Mitris in the mitral position have not yet been reported in the published literature. For now, this remains a theoretical advantage that awaits real-world confirmation.
Hemodynamic performance data, at least, continue to look encouraging. Across available studies, pressure gradients through the Mitris valve remain low and stable over time, and effective valve opening areas are maintained without signs of progressive narrowing.14Annals of Thoracic Surgery Short Reports. Clinical Outcomes of First-Time and Redo Mitral Valve Replacement Using MITRIS RESILIA Bioprosthesis That stability is what you want to see, because gradually rising gradients are typically the first measurable sign that a tissue valve is beginning to stiffen and fail. For the moment, the Mitris valve is doing what its tissue science predicted it would. Whether that holds into the second decade will determine whether it represents a genuine generational leap or merely an incremental improvement.